

APOS 27:

The Next Horizons in Precision Oncology

26–27 February 2027 | UNSW Sydney

Now in its 10th symposium, APOS 27 will explore emerging science, technologies and approaches shaping precision oncology — from identifying new therapeutic targets and treatment approaches to how advances are being translated into clinical care.

Here's a snapshot of what's planned across five sessions:

01 | New therapies and approaches

Emerging therapeutic targets and treatment approaches, including antibody-drug conjugates (ADCs), immuno-oncology, tumour evolution and resistance, and developments influencing early-phase trials.

02 | AI in oncology

How artificial intelligence is being applied across oncology, including radiation oncology, pathology and cancer screening.

03 | Germline, pharmacogenomics and more

The expanding role of germline genetics and pharmacogenomics in cancer care, alongside developments in ctDNA and liquid biopsy.

04 | Omics and new technologies

New approaches to understanding cancer biology, including the microbiome, spatial transcriptomics and proteomics.

05 | Live Molecular Oncology Board

A practical, case-based session following individual cancer cases from molecular pathology and genomic findings through to treatment considerations.

Featured speakers



Professor Eduardo Vilar-Sánchez
MD Anderson Cancer Centre

A clinician-scientist specialising in hereditary cancer syndromes and precision cancer prevention, Professor Vilar-Sánchez will bring an international perspective to the expanding role of germline genetics in precision oncology, including insights from his work in Lynch syndrome.



Professor Ben Solomon
Peter MacCallum Cancer Centre

An internationally recognised medical oncologist and clinician-researcher, Professor Solomon will explore tumour evolution, resistance to treatment and the role of repeat NGS.



Professor David Thomas
UNSW Sydney | Omico

A pioneer in precision oncology, Professor Thomas will examine developments in the real-world use of immuno-oncology therapies and their implications for precision cancer treatment.

They will be joined by leading clinicians, researchers and experts from across Australia, with further Australian and international speakers to be announced.

Program topics and speakers are subject to change.

